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Abstract: The major obstacle in the clinical use of the antitumor drug cisplatin is inherent and
acquired resistance. Typically, cisplatin resistance is not restricted to a single mechanism demanding
for a systems pharmacology approach to understand a whole cell’s reaction to the drug. In this
study, the cellular transcriptome of untreated and cisplatin-treated A549 non-small cell lung cancer
cells and their cisplatin-resistant sub-line A549rCDDP2000 was screened with a whole genome array
for relevant gene candidates. By combining statistical methods with available gene annotations
and without a previously defined hypothesis HRas, MAPK14 (p38), CCL2, DOK1 and PTK2B
were identified as genes possibly relevant for cisplatin resistance. These and related genes were
further validated on transcriptome (qRT-PCR) and proteome (Western blot) level to select candidates
contributing to resistance. HRas, p38, CCL2, DOK1, PTK2B and JNK3 were integrated into a model
of resistance-associated signalling alterations describing differential gene and protein expression
between cisplatin-sensitive and -resistant cells in reaction to cisplatin exposure.
Keywords: cisplatin resistance; cellular signalling; HRas; p38; CCL2; DOK1; PTK2B; JNK3
1. Introduction
Cisplatin is the backbone of treatment of non-small cell lung cancer (NSCLC). Patients with
advanced or metastatic disease receive a cisplatin-based combination therapy if they carry neither
an epithelial growth factor receptor (EGFR) nor an anaplastic lymphoma kinase (ALK) mutation [1].
One of the major drawbacks of this therapy is acquired resistance and the underlying mechanisms are
multifactorial. In recent years, research has focused on cell signalling, as several pathways seem to
play a major role in the development of chemoresistance. Signalling pathways, like extracellular-signal
regulated kinase (ERK1/2), phosphatidylinositide-3-kinase/protein kinase B (PI3K/Akt) or P38
mitogen-activated protein kinases (p38MAPK) pathway are involved in the cellular reaction to cisplatin
treatment [2,3]. Furthermore, tumour protein p53 (p53) signalling is a key pathway in apoptosis
triggered by cisplatin [4] and p53 mutations are often associated with cisplatin resistance [5]. In a
previous study, we found that cisplatin-resistant NSCLC cells are less susceptible to the drug-induced
G2/M cell cycle arrest and apoptosis as compared to the sensitive counterparts [6].
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Although many proteins and pathways relevant for cisplatin resistance have already been
identified, a broader insight into its multi-mechanistic nature requires a system-wide screening
approach. In the last decade, many high-throughput studies including functional screenings and
genotyping investigations using genomics, proteomics and other “omics” technologies have been
carried out [7]. Especially the latter genome-wide-scale experimental approaches provided a broader
insight into the molecular mechanisms of cisplatin resistance. Among others, Galuzzi et al. [8]
characterized the transcriptional response of A549 lung carcinoma cells to cisplatin in comparison
with C2-ceramide and cadmium chloride, both inducers of mitochondrial apoptosis. Here, cisplatin
showed a significantly different transcriptomic signature compared to the other two compounds.
Toshimitsu et al. used the cDNA microarray technology to find 44 differentially expressed genes
in sensitive and cisplatin-resistant oesophageal squamous cell carcinoma, among them 15 genes
encoding ribosome-related proteins [9]. Gatti et al. identified several regulated pathways in response
to cisplatin treatment in sensitive and resistant fission yeast strains [10]. The reaction to drug exposure
was strain-specific: proteasome-mediated protein degradation, heat shock response and DNA repair
were activated in cisplatin-sensitive yeast, whereas DNA mismatch repair, DNA damage recognition
and cell cycle progression were the predominantly induced pathways in resistant counterparts [10].
Another study of Cheng et al. analysed multiple sensitive/resistant ovarian carcinoma cell line pairs
using expression profiling [11]. The identified genes mostly belonged to cell surface interaction and
trafficking pathways, which were not previously associated with cisplatin resistance. Here, none
of the genes was differentially expressed in all six pairs of cells [11]. In a similar analysis by Yang
et al. in seven different cancer cell line pairs representing four types of cancer, three pathways
of differentially expressed genes were common for all pairs: leukocyte transendothelial migration,
phosphatidylinositol signalling and cell adhesionmolecules (CAMs) [12]. The authors compiled the 403
genes appearing in these pathways into a signalling network [12]. In another study of transcriptome
alterations in cisplatin-resistant A549/CDDP cells compared to the sensitive ones, Yang et al. built up a
systematic Ribonucleic acid (RNA)-network based on long noncoding RNA (lncRNA), protein-coding
messenger RNA (mRNA) and microRNA (miRNA) [13]. A similar comparison was done by Hu
et al., who analysed lncRNA and mRNA in A549 and the corresponding cisplatin-resistant variant
A549/DDP. They revealed 67 differentially expressed pathways including p53 signalling and cell cycle
regulation and generated a lncRNA-mRNA co-expression network [14]. Fang et al. also compared the
A549 lung carcinoma cell line with a cisplatin-resistant counterpart A549/DDP using a transcriptome
sequencing technique [15]. They identified in total 1214 differentially expressed genes. Most of these
genes were enriched in the PI3K/AKT, mitogen-activated protein kinase, actin cytoskeleton regulation
and focal adhesion pathways in the cisplatin-resistant subline [15].
Other groups focused on proteome profiling. Stewart et al. [16] identified 121 proteins differentially
expressed in sensitive and cisplatin-resistant ovarian carcinoma cells and correlated protein expression
with the respective mRNA levels. Another study utilized two-dimensional gel electrophoresis
combined with mass spectrometry to identify 12 differentially expressed proteins in the comparison of
cisplatin-sensitive and cisplatin-resistant A549/DDP lung carcinoma cells [17]. A recent report has
presented a novel approach to correlate protein levels with cisplatin sensitivity based on microwestern
arrays [18]. Such studies allow characterizing the effect of the drug on the cellular network of
interactions in relation to cisplatin resistance.
Systems pharmacology is an emerging field considering not a single interaction between a drug
and its target or pathway but the entire reaction of a cell to a drug exposure. A review by Wist
et al. defined systems pharmacology as an approach, which develops a global understanding of the
pathophysiology and the drug action on different organizational levels of a body system [19]. As the
overall body system could be too complex to analyse it at once, the authors subdivided the body into
an organ level, a tissue-cell level, an intracellular network level and a molecular level system, zooming
from global more and more into detail. According to that understanding, we chose the intracellular
network level as the starting point for our analysis.
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As a cellular model, we used the human adenocarcinoma alveolar basal epithelial, non-small cell
lung cancer cell line A549 and its cisplatin-resistant variant A549rCDDP2000 to identify key candidates
involved in cellular response to cisplatin treatment. For this purpose, we applied a data-driven method
using a whole genome array to investigate the entire transcriptome of our cell system after cisplatin
exposure. After identifying key candidates based on differential expression and gene annotation,




As a starting point for a data-driven approach, we used a whole genome array. The cells were
treated either with cisplatin or a drug-free medium (control cells). Cisplatin concentrations used
were cell line-dependent and based on the respective EC10 (respective concentration leading to 10%
of the maximum cytotoxic effect). This concentration enables assessing the transcriptional changes
resulting from pre-apoptotic signalling rather than the degradative effects in nearly dead cells. Thus,
the parental cells were treated with 11 µM cisplatin (EC10 of sensitive cell line). The resistant sub-line
was exposed to 11 µM and additionally treated with 34 µM cisplatin (the respective EC10). In the
following, “equimolar treatment” refers to the treatment of sensitive and resistant cell line with 11 µM
cisplatin and ‘equitoxic treatment’ refers to the treatment of the sensitive cell line with 11 µM cisplatin
and the resistant cell line with 34 µM cisplatin [6].
The data were processed as shown in Figure 1: After extracting differentially expressed genes, a
Gene Set Enrichment Analysis (GSEA) [20] was performed in order to identify key pathways altered
in response to cisplatin treatment. The set of differentially expressed genes was then reduced to
those involved in the identified pathways. The key candidates were validated using qRT-PCR and
Western blot.
 
Figure 1. Flow chart of the array data processing (FDR: false discovery rate; GO: Gene Ontology; WB:
Western blot).
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2.2. Microarray Analysis
2.2.1. Differentially Expressed Genes
By using a whole genome array, we investigated the transcriptome of both cell lines in different
treatment situations. The number of differentially expressed genes in the indicated comparisons of
treatment situations with at least twofold up- or down-regulation and a false discovery rate of 5%
in A549 and A549rCDDP2000 cells is presented in Table 1. The generated heat map of differentially
expressed genes shows a clear clustering between the different treatment conditions and cell types
based on an average linkage clustering using Pearson’s correlation distance (Figure 2).
Table 1. Number of differentially expressed genes, compared as treatment condition 1 vs. condition 2
with at least twofold up- or down-regulation and a false discovery rate of 5%.
Treatment Condition 1 Treatment Condition 2 Number of Differentially Expressed Genes
A549, untreated A549rCDDP2000, untreated 3697
A549, 11 µM cisplatin A549rCDDP2000, 11 µM cisplatin 4394
A549rCDDP2000, untreated A549rCDDP2000, 11 µM cisplatin 27
A549rCDDP2000, untreated A549rCDDP2000, 34 µM cisplatin 708
A549, untreated A549, 11 µM cisplatin 1191
A549, 11 µM cisplatin A549rCDDP2000, 34 µM cisplatin 3670
 
 
Figure 2. Heat map of the whole transcriptome, regulated genes with fold change cut-off at 2.0 and
a false discovery rate of 5% of all replicates in sensitive and resistant cells. Numbers above lanes
indicate: 1, 2, 3, 4: A549, untreated; 5, 6, 7: A549, treated with 11 µM cisplatin; 8, 9, 14, 15, 16:
A549rCDDP2000, untreated; 10, 11, 17, 18, 19: A549rCDDP2000, treated with 11 µM cisplatin; 12, 13,
20, 21, 22: A549rCDDP2000, treated with 34 µM cisplatin. The p-value (2.6 × 10−23) corresponds to
the result of a global test [21], which assesses the statistical significance of the entire signature that
discriminates A549 and A549rCDDP2000 cells.
The tree structure on top of the heat map indicates that A549 and A549rCDDP2000 cells cluster in
two clearly separated groups. Interestingly, this separation is not due to cisplatin treatment but marks
the differences between the cisplatin-sensitive vs. the cisplatin-resistant cell line. This shows that
the adaptation to cisplatin over a long time changes the expression pattern much more than a single
treatment with a higher dose. In the resistant cells, the difference in expression is dose-dependent, as
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cells treated with the higher dose cluster together. Furthermore, the number of differentially expressed
genes caused by cisplatin treatment is larger in sensitive cells than in the resistant cells, even after
exposure to the higher dose (Table 1). The technical validation of the microarray was performed by
qRT-PCR with ten up- or down regulated genes in all different treatment conditions. The results of the
qRT-PCR were consistent with the microarray data so that they were accepted as successfully validated.
2.2.2. Gene Set Enrichment Analysis
After the identification of differentially expressed genes, a Gene Set Enrichment Analysis
(GSEA) [20] was performed with respect to Gene Ontology (GO) terms [22] using HTSanalyzeR [23].
GSEA is a widely used method comparing the mapping of genes to a defined GO term with a ranking
of these genes, e.g., via logarithmic fold change. The GSEA method calculates a score assessing the
statistical significance of term enrichments with respect to the ranking of genes. More specifically,
GSEA tries to reject the null hypothesis that genes belonging to a certain set of interest (e.g., specific
GO biological process) are spread more or less uniformly all over the ranked list. On the other hand,
a statistically enriched gene set corresponds to a comparably high fraction (larger than expected by
chance) of its members appearing at the top or bottom of the ranked list.
Twelve GO terms were found to be statistically significant (FDR < 5%) associated with
cisplatin treatment: actin filament bundle assembly, cell surface receptor signalling pathway,
cytokine-mediated signalling pathway, cytoplasmic microtubule organization, hematopoietic
progenitor cell differentiation, negative regulation of osteoblast differentiation, NOTCH receptor
signalling, oocyte maturation, Ras protein signal transduction pathway, regulation of proteolysis,
response to testosterone stimulus, vascular endothelial growth factor receptor (VEGFR) signalling
pathway. The number of differentially expressed genes annotated with these twelve terms was far too
large for further analysis. Therefore, we focused on those terms, for which a contribution to the mode
of action of cisplatin or possible involvement in chemoresistance has been described in the literature,
namely NOTCH receptor signalling [24,25], the VEGFR signalling pathway [26,27], the cell surface
receptor signalling pathway [28,29] and the Ras protein signal transduction pathway [30,31].
Interestingly, these four pathways were significantly enriched in different comparisons as
indicated in Figure 3, e.g., the VEGFR pathway in treated with 11 µM cisplatin vs. untreated A549
cells. Importantly, the identified gene sets are not independent but share a number of differentially
expressed genes. Numbers in the fields on the diagram indicate the number of genes, which were
found in the indicated pathway. The yellow sections indicate those overlapping genes, which were
considered for further analysis (Figure 3).
ぼ
Figure 3. Venn diagram showing differentially expressed genes annotated with respective GO terms:
The yellow sections indicate those genes, which were chosen for validation.
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These shared genes comprise: HRas, MAPK14 (p38α, further referred to as p38), C-C motif
chemokine ligand 2 (CCL2), Docking protein 1 (DOK1), Docking protein 2 (DOK2), Protein tyrosine
kinase 2 beta (PTK2B), PTK2B (highly similar transcript variant) and MAP kinase-activated protein
kinase 2 (MAPKAPK2). For further investigation on mRNA and protein level, we decided to investigate
only one isoform of DOK, DOK1, because of the high similarity between them. As MAPKAPK2 is
directly associated downstream to p38 and directly regulated by p38 [32,33], we decided to analyse
only p38 as the superordinate mitogen-activated protein kinase. Only one isoform of PTK2B was
included in the validation. This data-driven method thus identified the following five key players for
further evaluation: HRas, p38, CCL2, DOK1 and PTK2B.
2.3. Evaluation of the Identified Candidates
After the transcriptomic analysis, the validation of the identified genes was performed on the
mRNA level by qRT-PCR and on protein level by Western blot analysis individually (Figure 4).
mRNA expression of HRas, a member of the oncogenic Ras family, was induced in both cell lines
after exposure to the equitoxic concentrations of cisplatin but not in resistant cells after treatment with
the equimolar concentration (11 µM). No significant changes were observed on protein level, although
a slight decrease in HRas expression after exposure to 11 µM and 34 µM cisplatin was detected in
A549rCDDP2000 cells (Figure 4).
MAPK14 (p38), a kinase involved in stress response and cell cycle alterations, was also induced
on mRNA level following cisplatin treatment but only in sensitive cells. Remarkably, the basal level
ofMAPK14 (p38) mRNA was significantly higher in resistant cells than in the sensitive cell line. In
A549rCDDP2000 cells,MAPK14 (p38) expression was significantly elevated after equitoxic treatment
(34 µM) compared to the equimolar concentration (11 µM cisplatin). These changes did not transfer
to the protein level as only a slight and not significant increase in basal p38 expression was found in
resistant cells compared to the sensitive ones (Figure 4).
CCL2, also known asMCP-1 (monocyte chemotactic protein 1), a cytokine gene associated with
invasion and metastasis, is connected to p38 [34,35]. Exposure to 11 µM cisplatin in A549 and to
34 µM cisplatin in A549rCDDP2000 cells significantly induced CCL2mRNA expression. Also in the
case of CCL2, mRNA expression in resistant cells was significantly higher after equitoxic compared
to equimolar treatment. No significant regulation could be observed on protein level after cisplatin
exposure (Figure 4).
DOK1 is known as a tumour suppressor protein and a negative regulator of tyrosine kinases in
mitogen-activated kinase signalling [36]. This candidate was not significantly influenced by cisplatin
exposure. However, both mRNA and protein levels were significantly higher in the resistant cell line
than in the sensitive counterpart, in untreated cells, as well as after equimolar and equitoxic treatment
(Figure 4).
PTK2B, also referred to as Pyk2, promotes tumour proliferation through activation of MAPK
signalling [37]. It also regulates response to cisplatin-induced stress through its interaction with
p53 [38]. After cisplatin exposure, its expression was decreased on mRNA level in sensitive but not in
resistant cells. PTK2B levels were therefore higher in the resistant cell line after equimolar treatment.
A slight but not significant reduction in PTK2B mRNA was observed in A549rCDDP2000 cells after
exposure to 34 µM cisplatin. No significant changes on protein level were found (Figure 4).
2.4. Extended Model of Resistance-Associated Signalling Alterations
After the evaluation of the key candidates, we took a closer look at the possible relationships
between them based on the literature evidence. DOK1 is known as a negative regulator of Ras [36,39].
HRas belongs to the Ras oncogene family being central to the MAPK/ERK pathway [30]. However,
the analysis of ERK activation revealed no significant differences between sensitive and resistant cell
line (Figure 5).
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Figure 4. mRNA expression (all n = 6) of HRas, MAPK14 (p38), CCL2, DOK1 and PTK2B related to
GAPDH mRNA expression; protein expression of HRas (n = 6), p38 (n = 6), CCL2 (n = 4), DOK1 (n =
7–8) and PTK2B (n = 3) related to GAPDH expression in A549 (ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱ) and A549rCDDP2000 (ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱȱ) before
(ctrl) and after treatment with 11 µM cisplatin (11) or 34 µM cisplatin (34) presented as mean ± SEM;
as well as representative Western blots. * p < 0.05; ** p < 0.01; *** p < 0.01.
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Figure 5. Expression of activated ERK (pERK1 and pERK2, both n = 7) related to GAPDH expression;
mRNA expression of JNK3 (n = 6) related to GAPDH mRNA expression; protein expression of JNK3
(n = 9) related to GAPDH expression; expression of activated p38 (p-p38, n = 4) related to GAPDH
expression in A549 (ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ) and A549rCDDP2000 (ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ) after treatment with 11 µM cisplatin (11) or 34 µM
cisplatin (34) expressed as mean ± SEM, as well as representative Western blots.* p < 0.05; ** p < 0.01;
*** p < 0.01.
On the other hand, HRas signalling reaches the nucleus via phosphorylation of c-Jun N-terminal
kinases (JNKs) [40,41], which in turn is able to stabilize p53 by hindering mouse double minute 2
homolog (MDM2) binding, increasing p53 activation and supporting p53-induced apoptosis [42].
Additionally, JNKs appear to phosphorylate p53 at various sites after DNA damage [43].
We have recently documented a role of p53 in cisplatin resistance in A549rCDDP2000 cells and
developed a model describing resistance-associated signalling alterations between the sensitive and
resistant cell line [6]. It should be noted that JNKs can activate the p53 effector GADD45a (a growth
arrest and DNA-damage inducible gene) also in the p53-independent manner [44]. For these reasons,
it appeared interesting to assess the relevance of JNK3, which was found to be differentially regulated
on the microarray, for cisplatin resistance in our cell model. Cisplatin treatment significantly reduced
JNK3 mRNA levels in sensitive and resistant cells (Figure 5). Interestingly, A549rCDDP2000 cells
expressed significantly higher basal levels of JNK3 mRNA compared to sensitive cells. Also after
equimolar and equitoxic treatment, JNK3 mRNA expression was elevated in the resistant cell line
compared to the sensitive one. No significant regulation of JNK3 on protein level was observed,
although a slight reduction in expression after treatment of resistant cells with 34 µM cisplatin could be
detected (Figure 5). As no specific antibody for p-JNK3, which would not detect p-JNK1 and p-JNK2,
is available, it was not possible to assess the activation status of this particular kinase.
PTK2B controls drug-induced apoptosis and cell survival by limiting p53 levels [38]. Another
important but positive, regulator of p53 is p38. It plays a key role in the induction of
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p53-mediated apoptosis by chemotherapeutic agents including cisplatin [45]. Therefore, we examined
phosphorylation of p38 in both cell lines before and after cisplatin treatment. As mentioned above, the
total protein expression of p38 was not different in sensitive and resistant cells and was not influenced
by cisplatin. As is clear from Figure 5, the platinum drug did not activate p38 in either cell line.
Nevertheless, basal phosphorylation level was significantly higher in A549rCDDP2000 cells. It was also
the case after equimolar and equitoxic treatment (Figure 5).
The interaction between p38 and CCL2 is bidirectional. On one hand, CCL2 was reported to
activate p38 [34]. In our case, cisplatin induced CCL2 expression in sensitive cells, which however did
not result in p38 activation. On the other hand, there is evidence that CCL2 expression is controlled by
p38 [35]. This is well in agreement with our data, as cisplatin exposure enhanced both p38 (MAPK14)
and CCL2mRNA expression in sensitive cells.
Based on the findings and literature evidence presented above we have extended the previous
model [6] summarizing the interactions between the identified candidates (Figure 6). In addition to
our previous work [6], we have now included the significant differences in basal mRNA or protein
expression, or kinase activation (indicated as red, green or blue circles, respectively) between sensitive
and resistant cells into the model as these are also relevant for cisplatin resistance as discussed below.
The model is based on the different reaction of A549 and A549rCDDP2000 cells to the equimolar
concentrations of cisplatin.
 
Figure 6. Model of resistance-associated signalling alterations indicating significant changes of mRNA
expression (red arrows) or protein expression (green arrows) after cisplatin treatment in A549 and
A549rCDDP2000 cells, as well as an increase in basal mRNA levels (red circles), protein levels (green
circles) or basal kinase activation (blue circles) in A549rCDDP2000 (b) compared to A549 (a) cells.
The model is based on the data presented and described here and the data previously published [6].
3. Discussion
3.1. Systems Pharmacology Approach
Earlier studies have clearly pointed out that a systems approach to address the problem of
chemoresistance to cisplatin has advantages over the conventional target-centred methodology, which
mainly identifies single proteins or a list of affected pathways [2,3,46] without displaying any functional
connections. Our previous work [6] utilized a common hypothesis-driven approach to characterize
cisplatin resistance in NSCLC cells and establish connections based on the literature evidence. Here,
Int. J. Mol. Sci. 2018, 19, 767 10 of 18
we have followed a data-driven top-down approach, which involves iterative filtering of the massive
amount of data of the whole genome microarray. This was done by statistical means without limiting
the results by a predefined hypothesis. Here, the reduction was done by choosing those differentially
expressed genes, which occurred simultaneously in different GO terms. This increased the a priori
chance of these genes to play a major role in cisplatin resistance. On the other hand, this way of
analysis could have led to the loss of relevant genes.
Nevertheless, by analysing not only the mRNA levels in a broad whole transcriptome approach
but adding the protein levels of the identified key candidates we could extend our previously
developed model of resistance-associated alterations [6]. As mentioned above, some high-content
analyses of cisplatin resistance using different techniques were performed in the last years. Galuzzi
et al. studied transcriptional alterations following cisplatin exposure in drug-sensitive A549 NSCLC
cells without comparing it with the corresponding resistant variant and analysing the connections
between the identified genes [8]. The identified cisplatin-induced modulations are different from our
findings. Noteworthy, the authors reported a surprisingly little overlap between their results [8] and
CDDP response modifiers found in a genome-wide siRNA screening in the same cells [47].
In an attempt to identify resistance-specific signatures, Yang et al. analysed the RNA expression
profiles of A549 and cisplatin-resistant A549/DDP lung carcinoma cells. They observed a clear
hierarchical clustering of the two cell lines, which is in agreement with our data. The validation by
qRT-PCR was performed on eight mRNAs implicated to be important for cisplatin resistance [13].
Interestingly, some of the significantly enriched signalling pathways from Yang et al. like MAPK
signalling [13] are similar to those identified in our study. Besides identifying a great number of
mRNAs differentially expressed in A549 and A549/CDDP cells, the authors conclude that cisplatin
resistance is also related to changes in long non-coding (lnc) RNAs. They also built up a signalling
network of those specific RNAs [13]. The importance of lncRNA was also highlighted by Hu et al. who
showed that knockdown of the aberrantly expressed lncRNA UCA1 sensitized resistant A549/DDP
cells to cisplatin [14]. The identified resistance-specific pathways like p53 signalling and cell cycle
correlate well with the results of our previous work [6].
Interestingly, in a comprehensive evaluation of seven sensitive/resistant cell line pairs a clear
clustering was observed for each pair [12]. The differentially regulated pathways common in all pairs
were different from those found in our study [12]. Nevertheless, the network included several genes
found relevant in our case, among themMDM2, PTK2B and p38MAPKs. In contrast, Fang et al. [15]
identified MAPK signalling as one of the pathways significantly altered in cisplatin-resistant
A549/DDP cells, which agrees well with our results and the findings of Yang et al. [13].
However, the effect of cisplatin on the RNA expression was not investigated in most studies. Only
Gatti et al. examined the effect of the platinum drug on the sensitive and resistant fission yeast strains
and documented strain-specific drug response [10]. Our findings show that not only the differences in
the basal gene or protein expression account for resistance but also the drug effect is altered in resistant
cells. Studying how a drug influences a whole cell system is a focus of systems pharmacology. In that
respect, we have done the first step towards the systems pharmacology approach in our cell model.
Zeng et al. compared the proteome of A549 cells and cisplatin-resistant A549/CDDP cells using
a combination of two-dimensional gel electrophoresis and mass spectrometry and identified twelve
resistance-related proteins, without compiling the data in a network and discussing interactions [17].
The identified proteins were different from our results, as the authors analysed the proteome level
and we based our protein analysis on previously found differences on mRNA level. It should also be
noted that the identification of differentially expressed proteins in the gel is intrinsically limited to the
abundant proteins as those are the most likely to be detected.
Furthermore, most studies did not include a robust validation of the identified targets on the
protein level. As is clear from our data, and has already been suggested by Stewart et al., changes
in mRNA expression do not necessarily correlate with protein abundance highlighting the need for
validation studies on both mRNA and protein level [16]. The authors carried out proteome profiling
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of sensitive and cisplatin-resistant ovarian carcinoma cells and correlated the results with mRNA
expression profiles. They found a discrepancy between mRNA and protein expression in more than
the half of the proteome indicating an important role of posttranscriptional regulation in controlling
protein expression [16]. Our findings also show a weak correlation between the mRNA and protein
data. This can be attributed to the choice of the time point of the measurement, to posttranscriptional
and posttranslational factors. The influence of translational efficiency and protein half-life on the
correlation between mRNA and protein levels is likely to be different for each gene and respective
protein demanding the systematic assessment of expression regulation [48]. Proteome profiling using
microwestern arrays [18] opens new opportunities to perform large-scale correlation studies between
gene and protein expression in context of cisplatin resistance. The recent report by Stark et al. [18] also
highlighted the importance of duration of cisplatin exposure for protein levels as the differences in
protein expression between sensitive and resistant cells altered greatly over time.
To the best of our knowledge, we are the first to investigate the reaction of resistant cells to
equimolar and equitoxic concentrations of cisplatin. The differences in the effect of the equimolar
concentrations on A549 and A549rCDDP2000 cells reflect the mechanisms of resistance. In most cases,
sensitive and resistant cells reacted similarly to the equitoxic concentrations. The absence of p38 and
PTK2B regulation in A549rCDDP2000 cells after treatment with 34 µM cisplatin is intriguing given the
same growth inhibitory effect in both cell lines. This underscores the fundamental differences between
the sensitive and resistant phenotype, which was also evident from the clear clustering of the two cell
lines on the heat map of differentially expressed genes.
3.2. Role of the Identified Key Players
Cisplatin leads to DNA damage through the formation of DNA adducts. This toxic insult triggers
activation of several different pathways for survival or apoptosis, depending on the amount of DNA
damage. In chemoresistant cancer cells, these pathways appear to be significantly dysregulated.
This work identified HRas, p38, CCL2, DOK1, PTK2B and JNK3 as key players of cisplatin
resistance. HRas is one of the genes of the Ras oncogenic family. Activating Rasmutations in several
cancer entities were held responsible for tumour development [49,50]. The connection between HRas
and cisplatin resistance was established already many years ago [51]. The absence of HRas regulation
after equimolar treatment in resistant cells may be a consequence of the elevated DOK1 expression
as DOK1 is a negative regulator of Ras [36,39]. One could expect that cisplatin-induced increase in
HRas expression in sensitive cells would result in higher JNK3 levels, which in turn would lead to an
activation of p53. However, cisplatin triggered down-regulation of JNK3 in both cell lines. Whereas
some studies documented the role of JNK signalling in p53 activation [42,43], others suggested the
JNK pathway to be a negative regulator of p53 [52]. Interestingly, A549rCDDP2000 cells feature higher
basal mRNA levels of JNK3 and TP53 (p53). It was shown in mantle cell lymphoma that consecutive
expression of JNK is required to promote proliferation [53]. Overexpression of TP53 (p53) mRNA is
common in cisplatin-resistant cancer cell lines [54] and was reported to correlate with resistance to the
drug in lung carcinoma patient samples [55]. It has been suggested that TP53 (p53) in resistant cells is
often mutated resulting in the loss of function, thus, not being able to mediate apoptosis [5].
PTK2B controls p53 through the regulation of the MDM2-associated p53 turnover. Its knockdown
was reported to increase p53 levels and inhibit cell proliferation [38], which is in agreement with our
results. On the other hand, the expression of PTK2B active domain in human fibroblasts blocked
cisplatin-induced apoptosis [38].
Another upstream regulator of p53 is p38. Cisplatin exposure increasedMAPK14 (p38) mRNA
expression in sensitive cells but not in resistant counterparts. However, the drug failed to activate p38
in both cell lines. Noteworthy, we detected the significantly higher basal levels ofMAPK14 (p38) mRNA
and an increase in basal p38 activation in A549rCDDP2000 cells, which is not uncommon. Fang et al.
observed increased expression of genes belonging to p38 MAPK pathway in cisplatin-resistant
A549/DDP cells compared to the parent cell line [15]. High levels of p38 have been associated
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with poor prognosis in other cancer entities [56]. Inhibition of p38 activation was reported to sensitize
tumour cells to cisplatin and etoposide [57,58].
As p38 regulates CCL2 expression [35], the observed increased CCL2 levels after cisplatin exposure
in sensitive cells but not in resistant cells were expected. These results suggest the relevance of CCL2
for cisplatin resistance in our cell model. A previous study showed that expression of CCL2 in ovarian
cancer cells correlates with chemotherapy response and is reduced in cisplatin-resistant cells [59].
Another study revealed that CCL2 expression is induced after treatment with cisplatin [60], which is in
agreement with our data.
3.3. Model of Resistance-Associated Signalling Alterations
Based on our results presented above, we built a preliminary signalling network, which can
explain the different reaction of the sensitive and resistant cell lines to cisplatin treatment (Figure 6).
Within the model we display possible connections between the identified key players, which could
serve as a basis for further hypotheses and investigations of the proteome. This could be limited by
the fact that the model is far not comprehensive and needs to be extended by further proteins, which
could additionally account for the effects on cell cycle and apoptosis. In our study, we had to reduce
the number of candidate genes and did not explore distinct perturbations of the signalling network.
On the other hand, the strength of the model is that the alterations in the gene and protein expression
are all based on experimental data. Our future work will focus on the validation and extension of
the model. Furthermore, the dynamic nature of mRNA and protein expression makes it necessary to
integrate the temporal dimension into the model.
At the end, our model aims at depicting the whole proteome and transcriptome allowing the
description of the response of all relevant signalling pathways to cisplatin exposure. Mathematical
models could make it possible to forecast the outcome of specific perturbations of the network serving
as a biomarker for chemotherapeutic response.
4. Materials and Methods
4.1. Drugs
Cis-diamminedichloroplatinum (II) (cisplatin) was obtained from Sigma–Aldrich, Steinheim,
Germany and dissolved in 0.9% sodium chloride (NaCl) to a concentration of 1.5 g/L. Aliquots were
stored at −20 ◦C and thawed immediately before use. Each aliquot was used only once. Cisplatin
cytotoxicity was assessed according to the previously described procedure [6] using freshly prepared
cisplatin solutions (A549: pEC50 = 4.500 ± 0.042, A549
rCDDP2000: pEC50 = 4.307 ± 0.030, mean ± SD,
n = 4) and compared to our previously published data obtained with aliquots of cisplatin solutions
(A549: pEC50 = 4.522 ± 0.144, n = 11, A549
rCDDP2000: pEC50 = 4.262 ± 0.171, n = 12, mean ± SD [6]).
Cytotoxicity was not significantly different (p > 0.05) and thus not influenced by the preparation
procedure. Individual pEC50 values for each independent experiment with freshly prepared cisplatin
solutions are summarized in Supplementary Table S1.
4.2. Cell Lines
The human NSCLC cell line A549 was obtained from American Type Culture Collection (ATCC)
(Manassas, VA, USA). Its cisplatin-resistant sub-line A549rCDDP2000 derived from the Resistant
Cancer Cell Line (RCCL) collection (www.kent.ac.uk/stms/cmp/RCCL/RCCLabout.html) had been
established by adapting the growth of A549 cells in the presence of increasing concentrations of cisplatin
until a final concentration of 2000 ng/mL cisplatin as described previously [61]. A549 cells were grown
in IMDMmedium (PAN-Biotech, Aidenbach, Germany) containing 4 mM L-glutamine supplemented
with 10% foetal calf serum, 100 I.E./mL penicillin and 0.1 mg/mL streptomycin. The medium of the
A549rCDDP2000 cells additionally contained 2 µg/mL cisplatin. Cells were cultivated as monolayers in
a humidified atmosphere at 37 ◦C and 5% CO2. Every ten passages, a new backup of cells was thawed
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to ensure the reproducibility of the results. For all experiments, cells were allowed to attach overnight,
experienced 4 h of serum starvation and were subsequently treated with cisplatin for 24 h in IMDM
medium without any supplements. The parental cells were treated with 11 µM cisplatin. The resistant
sub-line was exposed to 11 µM cisplatin and additionally treated with 34 µM cisplatin. The control cells
were treated with the drug-free medium. Prior serum starvation and the use of the unsupplemented
medium allowed us to avoid the influence of growth factors in serum on signalling response.
4.3. Microarray
Total ribonucleic acid (RNA) was isolated from the cells with my-Budget RNA Mini Kit
(Bio-Budget, Krefeld, Germany) through different spin columns according to the manufacturer’s
instructions. Isolated RNA was stored at −80 ◦C until analysis was performed.
Transcriptome was then analysed using One-Color Whole Genome Array SurePrint G3 Human
GE V2 8x60K Kit (Agilent Technologies, Santa Clara, CA, USA) according to the manufacturer’s
instructions. Briefly, total RNA was transcribed to complementary deoxyribonucleic acid (cDNA)
using AffinityScript-RT, Oligo dT-Promoter Primer and T7 RNA Polymerase and labelled using the One
Colour RNA Spike-In Kit (positive controls) including Cyanin 3-CTP (Cy3) dye. After purifying the
labelled/amplified complementary RNA (cRNA) using silica-membrane RNeasy spin columns from
the RNeasy® Mini Kit (Qiagen, Venlo, the Netherlands), cRNA was quantified spectrophotometrically
using NanoDropTM ND-1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA). 40 µL of equivalent
amounts of Cy3-labelled cRNA in 10× Blocking Agent and 25× Fragmentation Buffer, diluted with
2× GEx HI-RPM Hybridization Buffer were loaded on the gaskets of the microarray slide and kept
at 65 ◦C for 17 h with 10 rpm of agitation. After washing twice with different washing buffers,
the microarray was read out with the SureScan Microarray Scanner System (Agilent Technologies,
Santa Clara, CA, USA) to obtain immunofluorescence intensity. Array data were pre-processed
via background correction (exponential convolution method) [62] and quantile normalization [63].
Statistical significances of dose- and resistance-induced gene expression changes were analysed
using limma (Linear Models for Microarray Data, Bioconductor version 3.6, open source software
for bioinformatics) [64], a linear model-based technique. Differential expression was declared at a
5% false discovery rate (FDR) cut-off together with an at least twofold up- or downregulation. The
overall significance of the signature of differentially expressed genes was assessed via a global test [21].
The microarray data have been deposited into the Gene Expression Omnibus database under the
accession number GSE108214.
4.4. RNA Isolation, cDNA Synthesis and qRT-PCR
Whole cell RNA was isolated after treatment using the my-Budget RNAse Mini Kit (Bio-Budget,
Krefeld, Germany) and quantified spectrophotometrically with a NanoDropTM N-1000 (Thermo
Fisher Scientific Inc., Waltham, MA, USA). Subsequent cDNA synthesis was performed for 60 min
at 42 ◦C. The reaction mixture was composed of 2 µL water, 1.5 µL 10× buffer (Life Technologies,
Carlsbad, CA, USA), 1.1 µL MgCl2 solution (25 mM; Life Technologies, Carlsbad, CA, USA),
1.5 µL dithiothreitol solution (100 mM; Life Technologies, Carlsbad, CA, USA), 1.5 µL dNTP
(2.5 mM; Life Technologies, Carlsbad, CA, USA), 0.6 µL Rnasin® (20 U/µL; Life Technologies,
Carlsbad, CA, USA), 0.3 µL oligo-dT-primer (Life Technologies, Carlsbad, CA, USA) and
murine leukaemia virus reverse transcriptase (50 U/µL Life Technologies, Carlsbad, CA, USA).
qRT-PCR was performed according to the manufacturer’s instructions using the LightCycler®
480 SYBR Green I Master (Hoffmann La Roche, Basel, Switzerland). Primers (GTPase HRas:
forward 5′-TGGACGAATACGACCCCACT-3′, reverse 5′-CCAACGTGTAGAAGGCATCC-3′;
Mitogen-activated protein kinase 10 (JNK3): forward 5′-AAGCACCTCCATTCTGCTGG-3′,
reverse 5′-GGAAGGTGAGTCCCGCATAC-3′; P38 mitogen-activated protein kinases (p38):
forward 5′-TGCCGCTGGAAAATGTCTCA-3′, reverse 5′-GTTGTTCAGATCTGCCCCCA-3′;
C-C motif chemokine ligand 2 (CCL2): forward 5′-CGCCTCCAGCATGAAAGTCT-3′, reverse
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5′-TGTCTGGGGAAAGCTAGGGG-3′; protein tyrosine kinase 2 Beta (PTK2B): forward
5′-AAGGACATTGCCATGGAGCA-3′, reverse 5′-TGACCTTTTCAGCCTCCCAC-3′; Docking protein 1
(DOK1): forward 5′-TCTACCTGAGAAGGACGGCA-3′, reverse 5′-TCCAGGCACAGTCCAACATC-3′,
annealing temperature 60 ◦C) were purchased from Life Technologies, Carlsbad, CA, USA. Quality of
the qRT-PCR was proved by recording the melting curve of the DNA products. PCR experiments were
repeated six times for each gene. The results of individual experiments are presented in Supplementary
Table S2.
4.5. SDS-PAGE and Western Blot
Cellular proteins were extracted using RIPA buffer (50 mM Tris-HCl (pH 7.6), 150 mM NaCl,
1% Triton X-100, 1% sodium desoxycholate, 0.1% SDS, 1 mM EDTA) with protease inhibitors (2 µM
pepstatin, 2 µM leupeptin, protease inhibitor cocktail (Sigma-Aldrich, Steinheim, Germany), 1 mM
activated Na3VO4, 1 mM NaF). Protein concentrations were determined with the bicinchoninic acid
assay (BCA, Merck KGaA, Darmstadt, Germany). Whole protein extracts were separated using
polyacrylamide gel electrophoresis. Proteins were transferred to a PVDF membrane (Roti®-PVDF, Carl
Roth, Karlsruhe, Germany), which was blocked after protein transfer with 5% (w/v) not-fat dry milk
powder in Tris-buffered saline (TBS) with 0.1% (v/v) Tween-20 (TBS-T) for 1 h at room temperature.
Subsequently, the membranes were incubated overnight at 4 ◦C with primary goat antibodies diluted
in TBS-T (anti-HRas GTX-116041, 1:500; anti-JNK3 GTX-103148, 1:1000; anti-p38α GTX-110720, 1:500;
anti-DOK1 GTX-101610, 1:500, all GeneTex, Irvine, CA, USA; anti-CCL2 AVARP07046, 1:2000, Aviva
Systems Biology, San Diego, CA, USA; PTK2B H00002185-M01: 1:500, Abnova Corporation, Taipei
City, Taiwan; anti-p-p38α BYT-ORB6578, 1:1000, Biorbyt, Cambridge, UK) and washed three times
for 10 min with TBS-T followed by incubation with a primary goat antibody against glyceraldehyde
3-phosphate dehydrogenase (GAPDH) diluted in TBS-T (GTX100118, 1:20,000, GeneTex, Irvine, CA,
USA) for 30 min. at room temperature. After the washing steps the membranes were incubated with a
secondary HRP-conjugated antibody (goat anti-rabbit IgG-HRP SBA-4030-05, diluted 1:1000 in TBS-T,
Southern Biotech, Birmingham, AL, USA) for 1 h at room temperature. The detection was performed
with Enhanced Chemoluminescence (ECL) reagent (Pierce™ ECL Western Blotting Substrate, Thermo
Fisher Scientific Inc., Waltham, MA, USA) on a Molecular Imager ChemiDocTM XRS+ System from
Bio-Rad Laboratories GmbH, Munich, Germany. Densitometric analysis was carried out using Image
LabTM Software 6 (6.0, Bio-Rad Laboratories, Hercules, CA, USA) based on the results of three to
nine experiments as stated in the respective figure legends. The results of individual experiments are
presented in Supplementary Tables S3 and S4.
4.6. Statistical Analysis
All statistical analyses were performed using Prism® V6 (GraphPad Software, La Jolla, CA, USA).
Significance of differences in expression of the identified candidates was analysed based on logarithmic
values using a one-way analysis of variance (ANOVA) with a Holm-Sidak post-test. Differences were
considered to be statistically significant at p-value < 0.05.
5. Conclusions
This study identified several key players, such as HRas, p38, CCL2, DOK1, PTK2B and JNK3,
involved in the mechanisms of cisplatin resistance in NSCLC cells. In a model of signalling
alterations, we describe interactions of various proteins associated with cisplatin resistance and
provide a hypothesis how differences in their regulation may lead to the lack of cell cycle arrest
and apoptosis in resistant cells. Thus, our study can be regarded as the first step towards a systems
pharmacology approach, characterizing the reaction of the cellular system to cisplatin in the context of
cisplatin resistance.
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